Natera Inc (NTRA) FinancialsNTRANatera Inc

Natera, Inc. (NTRA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Insurance carriers, accounting for 93.7% of total sales, equivalent to $705.09M. Other significant revenue streams include Laboratory and other partners and Patients. Understanding this composition is critical for investors evaluating how NTRA navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Natera, Inc. maintains a gross margin of 63.70%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -10.07%, while the net margin is -8.90%. These profitability ratios, combined with a Return on Equity (ROE) of -12.54%, provide a clear picture of how effectively NTRA converts its operational activities into shareholder value.

In the context of the broader market, NTRA competes directly with industry leaders such as IQV and MRNA. With a market capitalization of $44.67B, it holds a significant position in the sector. When comparing efficiency, NTRA's gross margin of 63.70% stands against IQV's 26.17% and MRNA's 64.14%. Such benchmarking helps identify whether Natera, Inc. is trading at a premium or discount relative to its financial performance.

Natera has shown impressive revenue growth, with Q2 2026 revenue at $752.8 million, a 37.7% increase from the previous year, and a gross margin of 63.70%, indicating strong operational efficiency despite recent net losses.